Log in

OTCMKTS:NGSX - NeurogesX Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.0050
0.00 (0.00 %)
(As of 03/3/2016)
Add
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range N/A
52-Week Range
$0.00
Now: $0.01
$0.02
VolumeN/A
Average Volume70,548 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:NGSX
CUSIPN/A
Phone+1-650-3583300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NGSX News and Ratings via Email

Sign-up to receive the latest news and ratings for NGSX and its competitors with MarketBeat's FREE daily newsletter.


NeurogesX (OTCMKTS:NGSX) Frequently Asked Questions

What is NeurogesX's stock symbol?

NeurogesX trades on the OTCMKTS under the ticker symbol "NGSX."

Has NeurogesX been receiving favorable news coverage?

Headlines about NGSX stock have been trending negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeurogesX earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for NeurogesX.

What is NeurogesX's stock price today?

One share of NGSX stock can currently be purchased for approximately $0.01.

What is NeurogesX's official website?

The official website for NeurogesX is http://www.neurogesx.com/.

How can I contact NeurogesX?

NeurogesX's mailing address is 2215 Bridgepointe Pkwy Ste 200, FOSTER CITY, CA 94404-5067, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583300.


MarketBeat Community Rating for NeurogesX (OTCMKTS NGSX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  86
MarketBeat's community ratings are surveys of what our community members think about NeurogesX and other stocks. Vote "Outperform" if you believe NGSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel